Thymosin Alpha-1 (Tα1 / Thymalfasin) – Comprehensive Research Overview (2026)
Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino-acid peptide derived from the thymus gland. It is FDA-approved as an orphan drug (Zadaxin) for certain immunodeficiency conditions and is approved in over 35 countries for hepatitis B, hepatitis C, and as an adjuvant to cancer immunotherapy. Tα1 is one of the most clinically validated immunomodulatory peptides available, with a robust safety record spanning decades of use.
→ View Thymosin Alpha-1 (for laboratory research use only)
Chemical Structure and Properties
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (28 AA, N-terminally acetylated)
- Molecular Weight: ≈3,108 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: Thymus-derived immunomodulator with FDA orphan drug status and international approvals
Mechanism of Action
- Activates dendritic cells, NK cells, and T lymphocytes (particularly Th1 CD4+ and CD8+ cytotoxic T cells).
- Upregulates MHC class I and II expression, enhancing antigen presentation.
- Promotes IL-2, IFN-γ, and IL-12 production while modulating excessive inflammation.
- Activates TLR9 signaling, enhancing innate immune responses.
- Reduces immune exhaustion in chronic viral infections and cancer.
Clinical Evidence and Research Findings
Approved in 35+ countries for hepatitis B and C. Multiple RCTs demonstrate improved viral clearance, immune reconstitution, and survival in immunocompromised patients. Used as a vaccine adjuvant and cancer immunotherapy enhancer. COVID-19 research showed reduced mortality and improved immune recovery in severe cases. One of the most clinically validated immunomodulatory peptides available.
→ Interested in researching Thymosin Alpha-1? View Product Options
Benefits (Research & Clinical Observations)
- Enhanced T cell and NK cell activity
- Improved viral clearance (hepatitis B/C, COVID-19)
- Cancer immunotherapy adjuvant effects
- Vaccine response enhancement
- Immune reconstitution in immunodeficiency states
Typical Dosing Protocols
- Approved protocols: 1.6 mg subcutaneous twice weekly for 6–12 months (hepatitis)
- Off-label / research: 1–1.6 mg subcutaneous 1–2× weekly
- Cycles: Varies by indication; often 3–6 months
Safety Profile and Side Effects
Excellent safety profile with decades of clinical use. Common side effects: mild injection-site reactions. No significant immunosuppression, organ toxicity, or serious adverse events reported.
Summary
Thymosin Alpha-1 is one of the most clinically validated immunomodulatory peptides, with international approvals and a robust evidence base for viral infections, cancer immunotherapy, and immune reconstitution. Its favorable safety profile and broad immune-enhancing effects make it a cornerstone of immunology research. As with all compounds in this library, off-label use should only be considered under qualified medical supervision.
For Laboratory Research Use View Thymosin Alpha-1 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.